CREATIVE MEDICAL TECHNOLOGY

CELZNASDAQ

🏆 #3764 by market capEarnings Nov 6US Equity

$1.24▲ $0.04 (+3.33%)

Live

1h—

24h▲ 3.3%

7d—

14d—

30d—

1y—

🏦Market Cap

$6M

Small Cap

📈Revenue Growth (YoY)

-78.6%

Declining

📊Gross Margin

63.5%

High

💵FCF Margin

—

⚖️P/S Ratio

948.4x

Expensive

Otter Score

Fair

No chart data available for CELZ.

Trading Snapshot

Day Range: $1.22 – $1.26
52-Week Range: $0.62 – $6.25
Volume: $2.61B
Avg Volume: $3.05B
Shares Outstanding: 4.7M
Next Earnings: Oct 17, 2026

Fundamentals Snapshot

Annual Revenue: $6,000
Last Q Revenue: $1,355
P/E Ratio: —
P/S Ratio: 948.4x
EPS (TTM): $-2.04
Dividend Yield: —

Why Investors Own CELZ

✓High-growth profile — revenue up +7.9% YoY with expanding US Equity exposure.
✓Healthy economics — 57% gross margin and 30% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$6,000▲ +10.7% YoY

Gross Margin (TTM)

57.3%▲ +0.1% YoY

Operating Income (TTM)

$996▲ +10.7% YoY

Free Cash Flow (TTM)

$1,788▲ +10.7% YoY

About CREATIVE MEDICAL TECHNOLOGY

Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.

🦦